XML 75 R46.htm IDEA: XBRL DOCUMENT v3.24.0.1
Revenues (Details)
$ in Thousands
12 Months Ended
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Component
PerformanceObligation
Revenues [Abstract]      
Revenue $ 787,647 $ 587,367 $ 810,456
WAINUA (Eplontersen) Collaboration with AstraZeneca [Member]      
Revenues [Abstract]      
Revenue $ 20,000   $ 200,000
Number of material components | Component     4
Number of separate performance obligations | PerformanceObligation     1
Transaction price     $ 200,000
Percentage of costs associated with ongoing global Phase 3 development program paid by AstraZeneca 55.00%    
Commercial Revenue [Member]      
Revenues [Abstract]      
Revenue $ 308,591 303,358 342,395
SPINRAZA Royalties [Member]      
Revenues [Abstract]      
Revenue 240,379 242,314 267,776
Other Commercial Revenue [Member]      
Revenues [Abstract]      
Revenue 68,212 61,044 74,619
TEGSEDI and WAYLIVRA Revenue, Net [Member]      
Revenues [Abstract]      
Revenue 34,913 30,051 55,500
Licensing and Other Royalty Revenue [Member]      
Revenues [Abstract]      
Revenue 33,299 30,993 19,119
Research and Development Revenue [Member]      
Revenues [Abstract]      
Revenue 479,056 284,009 468,061
Collaborative Agreement Revenue [Member]      
Revenues [Abstract]      
Revenue 352,657 207,222 468,061
WAINUA Joint Development Revenue [Member]      
Revenues [Abstract]      
Revenue $ 126,399 $ 76,787 $ 0